{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:42:56Z","timestamp":1768344176085,"version":"3.49.0"},"reference-count":156,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T00:00:00Z","timestamp":1554163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Renal cell carcinoma (RCC) is the most common malignancy affecting the kidney. Current therapies are mostly curative for localized disease, but do not completely preclude recurrence and metastization. Thus, it is imperative to develop new therapeutic strategies based on RCC biological properties. Presently, metabolic reprograming and epigenetic alterations are recognized cancer hallmarks and their interactions are still in its infancy concerning RCC. In this review, we explore RCC biology, highlighting genetic and epigenetic alterations that contribute to metabolic deregulation of tumor cells, including high glycolytic phenotype (Warburg effect). Moreover, we critically discuss available data concerning epigenetic enzymes\u2019 regulation by aberrant metabolite accumulation and their consequences in RCC emergence and progression. Finally, we emphasize the clinical relevance of uncovering novel therapeutic targets based on epigenetic reprograming by metabolic features to improve treatment and survival of RCC patients.<\/jats:p>","DOI":"10.3390\/genes10040264","type":"journal-article","created":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T03:39:28Z","timestamp":1554262768000},"page":"264","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The Complex Interplay between Metabolic Reprogramming and Epigenetic Alterations in Renal Cell Carcinoma"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0441-6356","authenticated-orcid":false,"given":"Ana","family":"Lameirinhas","sequence":"first","affiliation":[{"name":"Cancer Biology &amp; Epigenetics Group\u2014Research Center, Portuguese Oncology Institute of Porto (CI-IPOP), 4200-072 Porto, Portugal"},{"name":"Master in Oncology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4231-5532","authenticated-orcid":false,"given":"Vera","family":"Miranda-Gon\u00e7alves","sequence":"additional","affiliation":[{"name":"Cancer Biology &amp; Epigenetics Group\u2014Research Center, Portuguese Oncology Institute of Porto (CI-IPOP), 4200-072 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3171-4666","authenticated-orcid":false,"given":"Rui","family":"Henrique","sequence":"additional","affiliation":[{"name":"Cancer Biology &amp; Epigenetics Group\u2014Research Center, Portuguese Oncology Institute of Porto (CI-IPOP), 4200-072 Porto, Portugal"},{"name":"Department of Pathology, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal"},{"name":"Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar\u2013 University of Porto (ICBAS-UP), 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4186-5345","authenticated-orcid":false,"given":"Carmen","family":"Jer\u00f3nimo","sequence":"additional","affiliation":[{"name":"Cancer Biology &amp; Epigenetics Group\u2014Research Center, Portuguese Oncology Institute of Porto (CI-IPOP), 4200-072 Porto, Portugal"},{"name":"Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar\u2013 University of Porto (ICBAS-UP), 4050-313 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2019,4,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., and Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.","DOI":"10.3322\/caac.21492"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.eururo.2011.06.049","article-title":"The epidemiology of renal cell carcinoma","volume":"60","author":"Ljungberg","year":"2011","journal-title":"Eur. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ucl.2004.01.004","article-title":"Risk factors for adult renal cell carcinoma","volume":"31","author":"Dhote","year":"2004","journal-title":"Urol. Clin. North Am."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000343534","article-title":"The epidemiology and risk factors for renal cancer","volume":"6","author":"Qayyum","year":"2012","journal-title":"Curr. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrurol.2015.232","article-title":"Gender differences in incidence and outcomes of urothelial and kidney cancer","volume":"12","author":"Lucca","year":"2015","journal-title":"Nat. Rev. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1158\/1055-9965.EPI-08-0601","article-title":"Family history and risk of renal cell carcinoma: Results from a case-control study and systematic meta-analysis","volume":"18","author":"Clague","year":"2009","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"v58","DOI":"10.1093\/annonc\/mdw328","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Escudier","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1590\/0100-3984.2013.1927","article-title":"Renal cell carcinoma: Histological classification and correlation with imaging findings","volume":"48","author":"Muglia","year":"2015","journal-title":"Radiol. Bras."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/ng.2904","article-title":"Intratumoral heterogeneity in kidney cancer","volume":"46","author":"Ricketts","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1053\/j.ackd.2013.10.001","article-title":"Hereditary kidney cancer syndromes","volume":"21","author":"Haas","year":"2014","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Research Network (2013). Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature, 499, 43\u201349.","DOI":"10.1038\/nature12222"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1158\/0008-5472.CAN-05-3074","article-title":"Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer","volume":"66","author":"Banks","year":"2006","journal-title":"Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1126\/science.1059817","article-title":"HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing","volume":"292","author":"Ivan","year":"2001","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1172\/JCI67230","article-title":"HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations","volume":"123","author":"Semenza","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nrc3844","article-title":"VHL, the story of a tumour suppressor gene","volume":"15","author":"Gossage","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/20459","article-title":"The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis","volume":"399","author":"Maxwell","year":"1999","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10409238.2013.838205","article-title":"Transcriptional regulation by hypoxia inducible factors","volume":"49","author":"Dengler","year":"2014","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.semcancer.2012.06.001","article-title":"The VHL\/HIF axis in clear cell renal carcinoma","volume":"23","author":"Shen","year":"2013","journal-title":"Semin. Cancer Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.eururo.2015.08.007","article-title":"Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer","volume":"69","author":"Schodel","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.critrevonc.2015.05.008","article-title":"Papillary renal cell carcinoma: A review of the current therapeutic landscape","volume":"96","author":"Courthod","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Research Network, Linehan, W.M., Spellman, P.T., Ricketts, C.J., Creighton, C.J., Fei, S.S., Davis, C., Wheeler, D.A., Murray, B.A., and Schmidt, L. (2016). Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N. Engl. J. Med., 374, 135\u2013145.","DOI":"10.1056\/NEJMoa1505917"},{"key":"ref_22","first-page":"537","article-title":"Papillary renal cell carcinoma: A clinicopathologic and immunohistochemical study of 105 tumors","volume":"10","author":"Delahunt","year":"1997","journal-title":"Mod. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1158\/1078-0432.CCR-13-2173","article-title":"MET is a potential target across all papillary renal cell carcinomas: Result from a large molecular study of pRCC with CGH array and matching gene expression array","volume":"20","author":"Albiges","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0002-9440(10)65147-4","article-title":"Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype","volume":"155","author":"Lubensky","year":"1999","journal-title":"Am. J. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/ng0597-68","article-title":"Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas","volume":"16","author":"Schmidt","year":"1997","journal-title":"Nat. Genet."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Haas, N.B., and Nathanson, K.L. (2014). Hereditary Renal Cancer Syndromes. Adv. Chronic Kidney Dis.","DOI":"10.1053\/j.ackd.2013.10.001"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1158\/1078-0432.CCR-06-0818","article-title":"Targeting the c-Met signaling pathway in cancer","volume":"12","author":"Peruzzi","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s11912-012-0230-3","article-title":"Renal cell carcinoma deep sequencing: Recent developments","volume":"14","author":"Farber","year":"2012","journal-title":"Curr. Oncol. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/ng849","article-title":"Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer","volume":"30","author":"Tomlinson","year":"2002","journal-title":"Nat. Genet."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ccr.2005.06.017","article-title":"HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability","volume":"8","author":"Isaacs","year":"2005","journal-title":"Cancer Cell"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Yang, Y., Lane, A.N., Ricketts, C.J., Sourbier, C., Wei, M.H., Shuch, B., Pike, L., Wu, M., Rouault, T.A., and Boros, L.G. (2013). Metabolic reprogramming for producing energy and reducing power in fumarate hydratase null cells from hereditary leiomyomatosis renal cell carcinoma. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0072179"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cmet.2007.10.002","article-title":"The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation","volume":"7","author":"DeBerardinis","year":"2008","journal-title":"Cell Metab."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: The metabolic requirements of cell proliferation","volume":"324","author":"Cantley","year":"2009","journal-title":"Science"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1126\/science.124.3215.267","article-title":"On respiratory impairment in cancer cells","volume":"124","author":"House","year":"1956","journal-title":"Science"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.3892\/ol.2012.928","article-title":"Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (Review)","volume":"4","author":"Zheng","year":"2012","journal-title":"Oncol. Lett."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/nrc1478","article-title":"Why do cancers have high aerobic glycolysis?","volume":"4","author":"Gatenby","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"24S","DOI":"10.2967\/jnumed.107.047258","article-title":"Causes and consequences of increased glucose metabolism of cancers","volume":"49","author":"Gillies","year":"2008","journal-title":"J. Nucl. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","article-title":"The emerging hallmarks of cancer metabolism","volume":"23","author":"Pavlova","year":"2016","journal-title":"Cell Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","article-title":"The Warburg Effect: How Does it Benefit Cancer Cells?","volume":"41","author":"Liberti","year":"2016","journal-title":"Trends Biochem. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.radonc.2009.06.025","article-title":"Pyruvate into lactate and back: From the Warburg effect to symbiotic energy fuel exchange in cancer cells","volume":"92","author":"Feron","year":"2009","journal-title":"Radiother. Oncol."},{"key":"ref_43","first-page":"3835","article-title":"Tumor metabolism: Cancer cells give and take lactate","volume":"118","author":"Semenza","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nrurol.2010.47","article-title":"The genetic basis of kidney cancer: A metabolic disease","volume":"7","author":"Linehan","year":"2010","journal-title":"Nat. Rev. Urol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.eururo.2012.09.054","article-title":"Metabolism of kidney cancer: From the lab to clinical practice","volume":"63","author":"Sudarshan","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10863-007-9081-2","article-title":"HIF-1 mediates the Warburg effect in clear cell renal carcinoma","volume":"39","author":"Semenza","year":"2007","journal-title":"J. Bioenerg. Biomembr."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.apsb.2015.05.007","article-title":"HIF-1\u03b1 pathway: Role, regulation and intervention for cancer therapy","volume":"5","author":"Masoud","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3892\/ijo.2015.3014","article-title":"Deregulation of energetic metabolism in the clear cell renal cell carcinoma: A multiple pathway analysis based on microarray profiling","volume":"47","author":"Soltysova","year":"2015","journal-title":"Int. J. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"151","DOI":"10.18632\/oncoscience.128","article-title":"Analysis and interpretation of transcriptomic data obtained from extended Warburg effect genes in patients with clear cell renal cell carcinoma","volume":"2","author":"Sanders","year":"2015","journal-title":"Oncoscience"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.bbrc.2015.03.130","article-title":"Metabolic signatures of renal cell carcinoma","volume":"460","author":"Lim","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40170-016-0154-8","article-title":"Novel drugs that target the metabolic reprogramming in renal cell cancer","volume":"4","author":"Panka","year":"2016","journal-title":"Cancer Metab."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/nrneph.2017.59","article-title":"Metabolic reprogramming in clear cell renal cell carcinoma","volume":"13","author":"Wettersten","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"274","DOI":"10.5489\/cuaj.10196","article-title":"Metabolic features of clear-cell renal cell carcinoma: Mechanisms and clinical implications","volume":"5","author":"Pinthus","year":"2011","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1002\/ijc.23403","article-title":"Metastasis is promoted by a bioenergetic switch: New targets for progressive renal cell cancer","volume":"122","author":"Langbein","year":"2008","journal-title":"Int. J. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.juro.2008.04.135","article-title":"Fatty acid synthase over expression is an indicator of tumor aggressiveness and poor prognosis in renal cell carcinoma","volume":"180","author":"Horiguchi","year":"2008","journal-title":"J. Urol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"6539","DOI":"10.1073\/pnas.1507228112","article-title":"MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism","volume":"112","author":"Shroff","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nrd3554","article-title":"Interfering with pH regulation in tumours as a therapeutic strategy","volume":"10","author":"Neri","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"388","DOI":"10.2174\/1568009616666151222150543","article-title":"Lactate Transporters and pH Regulation: Potential Therapeutic Targets in Glioblastomas","volume":"16","author":"Reis","year":"2016","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.semradonc.2004.04.004","article-title":"Lactate: Mirror and motor of tumor malignancy","volume":"14","author":"Walenta","year":"2004","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"6921","DOI":"10.1158\/0008-5472.CAN-11-1457","article-title":"Lactate: A metabolic key player in cancer","volume":"71","author":"Hirschhaeuser","year":"2011","journal-title":"Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00109-015-1307-x","article-title":"Hypoxia, cancer metabolism and the therapeutic benefit of targeting lactate\/H(+) symporters","volume":"94","author":"Marchiq","year":"2016","journal-title":"J. Mol. Med. (Berl.)"},{"key":"ref_62","first-page":"52","article-title":"Lactate Contribution to the Tumor Microenvironment: Mechanisms, Effects on Immune Cells and Therapeutic Relevance","volume":"7","year":"2016","journal-title":"Front. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1242\/dmm.007724","article-title":"Lactate shuttles at a glance: From physiological paradigms to anti-cancer treatments","volume":"4","author":"Draoui","year":"2011","journal-title":"Dis. Model. Mech."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Sonveaux, P., Copetti, T., De Saedeleer, C.J., Vegran, F., Verrax, J., Kennedy, K.M., Moon, E.J., Dhup, S., Danhier, P., and Frerart, F. (2012). Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0033418"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1158\/0008-5472.CAN-10-2828","article-title":"Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-kappaB\/IL-8 pathway that drives tumor angiogenesis","volume":"71","author":"Vegran","year":"2011","journal-title":"Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.cell.2015.03.011","article-title":"A lactate-induced response to hypoxia","volume":"161","author":"Lee","year":"2015","journal-title":"Cell"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nature13490","article-title":"Functional polarization of tumour-associated macrophages by tumour-derived lactic acid","volume":"513","author":"Colegio","year":"2014","journal-title":"Nature"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.radonc.2009.11.007","article-title":"Glycolytic metabolism and tumour response to fractionated irradiation","volume":"94","author":"Sattler","year":"2010","journal-title":"Radiother. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nrg.2016.59","article-title":"The molecular hallmarks of epigenetic control","volume":"17","author":"Allis","year":"2016","journal-title":"Nat. Rev. Genet."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nsmb.2489","article-title":"Epigenetic programming and reprogramming during development","volume":"20","author":"Cantone","year":"2013","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Flavahan, W.A., Gaskell, E., and Bernstein, B.E. (2017). Epigenetic plasticity and the hallmarks of cancer. Science, 357.","DOI":"10.1126\/science.aal2380"},{"key":"ref_72","unstructured":"Egger, G., and Arimondo, P. (2015). Cancer Epigenetics. Drug Discovery in Cancer Epigenetics, Academic Press. [1st ed.]."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nature02625","article-title":"Epigenetics in human disease and prospects for epigenetic therapy","volume":"429","author":"Egger","year":"2004","journal-title":"Nature"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1038\/ncponc0354","article-title":"DNA methylation and gene silencing in cancer","volume":"2","author":"Baylin","year":"2005","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"18347","DOI":"10.1074\/jbc.R110.205286","article-title":"DNA methylation and demethylation in mammals","volume":"286","author":"Chen","year":"2011","journal-title":"J Biol. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/0092-8674(92)90611-F","article-title":"Targeted mutation of the DNA methyltransferase gene results in embryonic lethality","volume":"69","author":"Li","year":"1992","journal-title":"Cell"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0092-8674(00)81656-6","article-title":"DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development","volume":"99","author":"Okano","year":"1999","journal-title":"Cell"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1126\/science.1210597","article-title":"Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine","volume":"333","author":"Ito","year":"2011","journal-title":"Science"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/B978-0-12-380866-0.60002-2","article-title":"DNA methylation and cancer","volume":"Volume 70","author":"Herceg","year":"2010","journal-title":"Advances in Genetics"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrg1655","article-title":"DNA methylation and human disease","volume":"6","author":"Robertson","year":"2005","journal-title":"Nat. Rev. Genet."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","article-title":"Chromatin modifications and their function","volume":"128","author":"Kouzarides","year":"2007","journal-title":"Cell"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"RE4","DOI":"10.1126\/sageke.2003.14.re4","article-title":"The constantly changing face of chromatin","volume":"2003","author":"Vaquero","year":"2003","journal-title":"Sci. Aging Knowl. Environ."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13045-016-0279-9","article-title":"Targeting histone methylation for cancer therapy: Enzymes, inhibitors, biological activity and perspectives","volume":"9","author":"Song","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2007.01.015","article-title":"The role of chromatin during transcription","volume":"128","author":"Li","year":"2007","journal-title":"Cell"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/ng1531","article-title":"Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer","volume":"37","author":"Fraga","year":"2005","journal-title":"Nat. Genet."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev.biochem.70.1.81","article-title":"Histone acetyltransferases","volume":"70","author":"Roth","year":"2001","journal-title":"Annu. Rev. Biochem."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1126\/science.1063127","article-title":"Translating the histone code","volume":"293","author":"Jenuwein","year":"2001","journal-title":"Science"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"a018713","DOI":"10.1101\/cshperspect.a018713","article-title":"Erasers of histone acetylation: The histone deacetylase enzymes","volume":"6","author":"Seto","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1080\/14756366.2017.1417274","article-title":"Zinc binding groups for histone deacetylase inhibitors","volume":"33","author":"Zhang","year":"2018","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/35001622","article-title":"Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase","volume":"403","author":"Imai","year":"2000","journal-title":"Nature"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1177\/1947601911417176","article-title":"Histone modifiers in cancer: Friends or foes?","volume":"2","author":"Cohen","year":"2011","journal-title":"Genes Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.3171\/2013.9.JNS13511","article-title":"Prognostic relevance of global histone 3 lysine 9 acetylation in ependymal tumors","volume":"119","author":"Ebrahimi","year":"2013","journal-title":"J. Neurosurg."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nrg3142","article-title":"Epigenetics and the environment: Emerging patterns and implications","volume":"13","author":"Feil","year":"2012","journal-title":"Nat. Rev. Genet."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrneph.2016.168","article-title":"The epigenetic landscape of renal cancer","volume":"13","author":"Morris","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Malouf, G., Zhang, J., Tannir, N.M., Thompson, E., Spano, J.-P., Khayat, D., and Su, X. (2014). Association of CpG island methylator phenotype with clear-cell renal cell carcinoma aggressiveness. J. Clin. Oncol.","DOI":"10.1200\/jco.2014.32.15_suppl.4574"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-015-0180-y","article-title":"Role of DNA methylation in renal cell carcinoma","volume":"8","author":"Shenoy","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1158\/1078-0432.CCR-14-0494","article-title":"Kidney cancer is characterized by aberrant methylation of tissue-specific enhancers that are prognostic for overall survival","volume":"20","author":"Hu","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/PPO.0b013e3182a102d1","article-title":"PBRM1 and BAP1 as novel targets for renal cell carcinoma","volume":"19","author":"Brugarolas","year":"2013","journal-title":"Cancer J."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1470-2045(12)70584-3","article-title":"Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: A retrospective analysis with independent validation","volume":"14","author":"Kapur","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1002\/ijc.27822","article-title":"Loss of PBRM1 expression is associated with renal cell carcinoma progression","volume":"132","author":"Pawlowski","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrc2876","article-title":"Covalent histone modifications\u2014Miswritten, misinterpreted and mis-erased in human cancers","volume":"10","author":"Chi","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1002\/ijc.25250","article-title":"Prognostic relevance of global histone H3 lysine 4 (H3K4) methylation in renal cell carcinoma","volume":"127","author":"Ellinger","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.2353\/ajpath.2009.080874","article-title":"Global levels of histone modifications predict prognosis in different cancers","volume":"174","author":"Seligson","year":"2009","journal-title":"Am. J. Pathol."},{"key":"ref_104","first-page":"879","article-title":"Decreased levels of histone H3K9me1 indicate poor prognosis in patients with renal cell carcinoma","volume":"32","author":"Rogenhofer","year":"2012","journal-title":"Anticancer Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1464-410X.2011.10278.x","article-title":"Global histone H3 lysine 27 (H3K27) methylation levels and their prognostic relevance in renal cell carcinoma","volume":"109","author":"Rogenhofer","year":"2012","journal-title":"BJU Int."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Fritzsche, F.R., Weichert, W., Roske, A., Gekeler, V., Beckers, T., Stephan, C., Jung, K., Scholman, K., Denkert, C., and Dietel, M. (2008). Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer, 8.","DOI":"10.1186\/1471-2407-8-381"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1158\/1078-0432.CCR-08-1918","article-title":"Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells","volume":"15","author":"Cha","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Ramakrishnan, S., Ku, S., Ciamporcero, E., Miles, K.M., Attwood, K., Chintala, S., Shen, L., Ellis, L., Sotomayor, P., and Swetzig, W. (2016). HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2604-7"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3233\/CBM-160298","article-title":"HDAC6 serves as a biomarker for the prognosis of patients with renal cell carcinoma","volume":"19","author":"Zhang","year":"2017","journal-title":"Cancer Biomark."},{"key":"ref_110","first-page":"4647","article-title":"HDAC9 associates with distant metastasis and predicts poor prognosis in clear cell renal cell cancer","volume":"10","author":"Liang","year":"2017","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1111\/j.1349-7006.2010.01717.x","article-title":"Global histone acetylation levels: Prognostic relevance in patients with renal cell carcinoma","volume":"101","author":"Mosashvilli","year":"2010","journal-title":"Cancer Sci."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.juro.2008.04.136","article-title":"Decreased acetylation of histone H3 in renal cell carcinoma: A potential target of histone deacetylase inhibitors","volume":"180","author":"Kanao","year":"2008","journal-title":"J. Urol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"675.e9","DOI":"10.1016\/j.urolonc.2017.08.016","article-title":"Differential expression of the sirtuin family in renal cell carcinoma: Aspects of carcinogenesis and prognostic significance","volume":"35","author":"Jeh","year":"2017","journal-title":"Urol. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/nrc3985","article-title":"The multifaceted functions of sirtuins in cancer","volume":"15","author":"Chalkiadaki","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.molcel.2010.05.023","article-title":"Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha","volume":"38","author":"Lim","year":"2010","journal-title":"Mol. Cell"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.cell.2009.12.041","article-title":"The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha","volume":"140","author":"Zhong","year":"2010","journal-title":"Cell"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1038\/onc.2011.37","article-title":"SirT3 suppresses hypoxia inducible factor 1alpha and tumor growth by inhibiting mitochondrial ROS production","volume":"30","author":"Bell","year":"2011","journal-title":"Oncogene"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1038\/onc.2016.485","article-title":"Interplay between epigenetics and metabolism in oncogenesis: Mechanisms and therapeutic approaches","volume":"36","author":"Wong","year":"2017","journal-title":"Oncogene"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3389\/fgene.2018.00427","article-title":"Metabolism and epigenetic interplay in cancer: Regulation and putative therapeutic targets","volume":"9","author":"Lameirinhas","year":"2018","journal-title":"Front. Genet."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3389\/fendo.2017.00304","article-title":"Cofactors as metabolic sensors driving cell adaptation in physiology and disease","volume":"8","author":"Rabhi","year":"2017","journal-title":"Front. Endocrinol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/nrc.2016.82","article-title":"Metabolic control of epigenetics in cancer","volume":"16","author":"Kinnaird","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"11560","DOI":"10.1158\/0008-5472.CAN-06-1950","article-title":"SLC5A8 triggers tumor cell apoptosis through pyruvate-dependent inhibition of histone deacetylases","volume":"66","author":"Thangaraju","year":"2006","journal-title":"Cancer Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1093\/nar\/gks066","article-title":"Lactate, a product of glycolytic metabolism, inhibits histone deacetylase activity and promotes changes in gene expression","volume":"40","author":"Latham","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12964-015-0114-x","article-title":"L- and D-lactate enhance DNA repair and modulate the resistance of cervical carcinoma cells to anticancer drugs via histone deacetylase inhibition and hydroxycarboxylic acid receptor 1 activation","volume":"13","author":"Wagner","year":"2015","journal-title":"Cell Commun. Signal."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.4161\/cc.10.8.15330","article-title":"Ketones and lactate increase cancer cell \u201cstemness\u201d, driving recurrence, metastasis and poor clinical outcome in breast cancer: Achieving personalized medicine via Metabolo-Genomics","volume":"10","author":"Prisco","year":"2011","journal-title":"Cell Cycle"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2485S","DOI":"10.1093\/jn\/133.7.2485S","article-title":"Inhibition of histone deacetylase activity by butyrate","volume":"133","author":"Davie","year":"2003","journal-title":"J. Nutr."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.diabres.2014.08.009","article-title":"\u03b2-hydroxybutyrate: Much more than a metabolite","volume":"106","author":"Newman","year":"2014","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.molcel.2012.08.033","article-title":"The Warburg effect dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation","volume":"48","author":"Donohoe","year":"2012","journal-title":"Mol. Cell"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40170-017-0166-z","article-title":"The action of beta-hydroxybutyrate on the growth, metabolism and global histone H3 acetylation of spontaneous mouse mammary tumours: Evidence of a beta-hydroxybutyrate paradox","volume":"5","author":"Rodrigues","year":"2017","journal-title":"Cancer Metab."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1126\/science.1227166","article-title":"Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor","volume":"339","author":"Shimazu","year":"2013","journal-title":"Science"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/abbs\/gmt148","article-title":"Hypoxia and cancer cell metabolism","volume":"46","author":"Huang","year":"2014","journal-title":"Acta Biochim. Biophys. Sin. (Shanghai)"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.cmet.2015.05.014","article-title":"Acetyl coenzyme A: A central metabolite and second messenger","volume":"21","author":"Pietrocola","year":"2015","journal-title":"Cell Metab."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4062\/biomolther.2017.185","article-title":"Metabolic Signaling to Epigenetic Alterations in Cancer","volume":"26","author":"Kim","year":"2018","journal-title":"Biomol. Ther. (Seoul)"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1126\/science.1164097","article-title":"ATP-citrate lyase links cellular metabolism to histone acetylation","volume":"324","author":"Wellen","year":"2009","journal-title":"Science"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmet.2014.06.004","article-title":"Akt-dependent metabolic reprogramming regulates tumor cell histone acetylation","volume":"20","author":"Lee","year":"2014","journal-title":"Cell Metab."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"11960","DOI":"10.1038\/ncomms11960","article-title":"Acetate functions as an epigenetic metabolite to promote lipid synthesis under hypoxia","volume":"7","author":"Gao","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.celrep.2016.10.012","article-title":"Lipids Reprogram Metabolism to Become a Major Carbon Source for Histone Acetylation","volume":"17","author":"McDonnell","year":"2016","journal-title":"Cell Rep."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1101\/gad.191056.112","article-title":"Inhibition of alpha-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors","volume":"26","author":"Xiao","year":"2012","journal-title":"Genes Dev."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1074\/jbc.M115.688762","article-title":"Fumarate and Succinate Regulate Expression of Hypoxia-inducible Genes via TET Enzymes","volume":"291","author":"Laukka","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.ccr.2013.04.018","article-title":"SDH mutations establish a hypermethylator phenotype in paraganglioma","volume":"23","author":"Letouze","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"32955","DOI":"10.18632\/oncotarget.5106","article-title":"Deciphering the molecular basis of invasiveness in Sdhb-deficient cells","volume":"6","author":"Loriot","year":"2015","journal-title":"Oncotarget"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature19353","article-title":"Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition","volume":"537","author":"Sciacovelli","year":"2016","journal-title":"Nature"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1158\/2159-8290.CD-13-0696","article-title":"L-2-Hydroxyglutarate: An epigenetic modifier and putative oncometabolite in renal cancer","volume":"4","author":"Shim","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.cmet.2015.06.021","article-title":"Hypoxia-Mediated Increases in L-2-hydroxyglutarate Coordinate the Metabolic Response to Reductive Stress","volume":"22","author":"Oldham","year":"2015","journal-title":"Cell Metab."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.cmet.2015.06.023","article-title":"Hypoxia Induces Production of L-2-Hydroxyglutarate","volume":"22","author":"Intlekofer","year":"2015","journal-title":"Cell Metab."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","article-title":"Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases","volume":"19","author":"Xu","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/embor.2011.43","article-title":"The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases","volume":"12","author":"Chowdhury","year":"2011","journal-title":"EMBO Rep."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.freeradbiomed.2016.04.025","article-title":"Oncometabolites: Unconventional triggers of oncogenic signalling cascades","volume":"100","author":"Sciacovelli","year":"2016","journal-title":"Free Radic. Biol. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"483","DOI":"10.18632\/oncoscience.165","article-title":"Another small molecule in the oncometabolite mix: L-2-Hydroxyglutarate in kidney cancer","volume":"2","author":"Shim","year":"2015","journal-title":"Oncoscience"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3109\/00365590903286697","article-title":"Prognostic factors and long-term survival in renal cell cancer patients","volume":"43","author":"Sunela","year":"2009","journal-title":"Scand. J. Urol. Nephrol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-0033-1363840","article-title":"Surgical management of renal cell carcinoma","volume":"31","author":"Krabbe","year":"2014","journal-title":"Semin. Intervent. Radiol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3816\/CGC.2005.n.030","article-title":"Cytokine therapy: A standard of care for metastatic renal cell carcinoma?","volume":"4","author":"Hutson","year":"2005","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1080\/14737140.2016.1222908","article-title":"Renal cell cancer: Overview of the current therapeutic landscape","volume":"16","author":"Erman","year":"2016","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_154","first-page":"244","article-title":"Targeted therapy for renal cell carcinoma: A new treatment paradigm","volume":"20","author":"Hutson","year":"2007","journal-title":"Proc. (Bayl. Univ. Med. Cent.)"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1200\/JCO.2005.04.8280","article-title":"Renal cell carcinoma recurrence after nephrectomy for localized disease: Predicting survival from time of recurrence","volume":"24","author":"Eggener","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.juro.2008.05.006","article-title":"Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma","volume":"180","author":"Eggener","year":"2008","journal-title":"J. Urol."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/10\/4\/264\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:42:16Z","timestamp":1760186536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/10\/4\/264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,2]]},"references-count":156,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,4]]}},"alternative-id":["genes10040264"],"URL":"https:\/\/doi.org\/10.3390\/genes10040264","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,2]]}}}